GlassScriptPhysician profile
Nicholas T Pecorelli
NPI 1699744755
$12,559.15
in general payments reported to CMS, 2019-2025
54 companies · $1,405 in 2025
The $1,405 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,201 · 2020: $2,131 · 2021: $2,026 · 2022: $1,877 · 2023: $1,541 · 2024: $1,378 · 2025: $1,405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,324.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,226.68 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $857.53 | 2019-2025 | Farxiga, Airsupra, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $772.80 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Kowa Pharmaceuticals America, INC. | $693.19 | 2019-2025 | Zoryve, Livalo, Seglentis |
| Abbott Laboratories | $632.48 | 2020-2025 | Freestyle Libre |
| Lilly USA, LLC | $594.66 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Amgen INC. | $528.20 | 2019-2025 | Otezla, Repatha, Repatha |
| Amarin Pharma, INC. | $476.43 | 2019-2021 | |
| Abbvie INC. | $442.09 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $407.01 | 2019-2023 | Belsomra, Steglatro |
| Glaxosmithkline, LLC. | $365.86 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $343.59 | 2019-2025 | |
| Allergan, INC. | $336.73 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $311.47 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $289.94 | 2019-2022 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Pecorelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.